How to judge a peptide study: animal vs human evidence, sample size and red flags

Check whether a peptide study was done in people, compared against a control group and repeated by others; this page shows how, with examples from our library, and recommends no compound.

Basics8 min read

Key takeaway

A cell or animal result is a starting point, not proof that something works in people. The strongest evidence comes from registered, randomized, controlled human trials that other groups can repeat. Promising drugs often fail. FDA estimates that only about 25% to 30% of drugs in Phase 3 move on to the next phase. Check who ran the study, who paid for it, and whether it measured an outcome you actually care about.

At a glance

Article typeBasics
TopicPeptide science
Studies cited9
Related productsResearch peptide catalog

To judge a peptide study, check whether it was done in people, compared against a control group, and repeated by other researchers. Most claims about research peptides fail at least one of those checks. This page shows how to read a study the way a careful clinician would, using real examples from our library. It does not recommend any compound. Sources were checked on November 17, 2026.

Quick answer: Are peptides worth it? That depends on the specific compound and the evidence behind it, and for most research peptides the human evidence is thin or missing. Approved peptide medicines have passed FDA review for specific uses, and a prescriber decides whether one fits. Research-grade peptides are laboratory reagents for laboratory research use only, not for human or veterinary use.

What is the evidence ladder?

Evidence about a compound builds in steps. FDA lists two kinds of preclinical research, in vitro (lab) and in vivo (animal), done before testing in people (FDA, 2018). It says preclinical research is "not a substitute for studies of ways the drug will interact with the human body" (FDA, 2018). An NIH guide says clinical trials "give the clearest information" about whether a treatment works and is safe in people (NCCIH).

Even good early results often fail later. FDA estimates that about 70% of drugs move past Phase 1. Only about 33% move past Phase 2, and about 25% to 30% past Phase 3. Table 1 shows each step with an example from our library.

Table 1

The evidence ladder, with peptide examples (checked November 17, 2026)

Step What it can show What it cannot show Example
Cell (in vitro) study A biological effect in a dish Any effect in a whole body Epithalon raised telomerase activity in cultured human fetal cells (Khavinson, 2003)
Animal study Effects in a living animal That people respond the same way MOTS-c prevented diet-induced obesity and insulin resistance in mice (Lee, 2015)
Small human report, no control group That people tried it and what they reported Whether it beat placebo or natural recovery 7 of 12 patients reported knee pain relief in a retrospective BPC-157 study (Vasireddi, 2025)
Randomized controlled trial Whether it beats placebo in a defined group Long-term safety, or results in other groups Retatrutide Phase 2: 338 adults, double-blind, placebo-controlled (Jastreboff, 2023)
Large outcome trial Effects on events like heart attack or death Effects outside the population studied SELECT: 17,604 patients, cardiovascular events measured directly (Lincoff, 2023)

The retatrutide example shows that a strong trial still is not approval. Retatrutide had a randomized Phase 2 trial and has moved into Phase 3, yet FDA has not approved it. Our retatrutide research summary covers where that work stands.

Why do study size and a control group matter?

Small studies can mislead by chance. NIH guidance says "small sample sizes are more likely to produce results due to chance" (NCCIH). A control group matters too. In a controlled trial, one group gets the treatment and a similar group gets standard care or an inactive substance (NCCIH). Blinding keeps participants and researchers from knowing who got what, which reduces bias.

Ipamorelin shows why a control group changes the picture. In a randomized, double-blind Phase 2 trial after bowel surgery, 114 patients were analyzed. There were no significant differences between ipamorelin and placebo on the main efficacy measures (Beck et al., 2014). Without a placebo group, any recovery could have looked like a drug effect. See our ipamorelin research summary.

Was the trial registered before it started?

Medical journal editors ask that trials be registered in a public registry before the first participant enrolls. The International Committee of Medical Journal Editors says this guards against "selective publication and selective reporting of research outcomes" (ICMJE). ClinicalTrials.gov is one accepted registry.

Look for a registration number such as "NCT" followed by eight digits in the abstract. The retatrutide Phase 2 paper lists NCT04881760, and the ipamorelin trial lists NCT00672074. Search that number on ClinicalTrials.gov and compare the planned main outcome with what the paper reports. Our guide to finding a peptide clinical trial explains the registry in more detail.

Has anyone outside the original lab repeated it?

NIH notes that when many studies reach the same conclusion, "it helps us know that the results are reliable and valid" (NCCIH). BPC-157 is the clearest single-lab example in peptide research. A PubMed search on November 17, 2026 found 232 records mentioning BPC-157 (PubMed, 2026). Of those, 175 list Predrag Sikiric of the University of Zagreb as an author. None was tagged as a randomized controlled trial.

Independent reviews reach the same limit. A 2025 systematic review included 36 BPC-157 studies, 35 of them preclinical, and found no clinical safety data (Vasireddi et al., 2025). Another 2025 review counted only three human pilot studies (McGuire et al., 2025). A single-lab finding is not necessarily wrong, but it is not yet independently confirmed. Our BPC-157 research summary goes through the studies.

Does the study measure what you actually care about?

Many studies measure a marker instead of the result people want. FDA defines a surrogate endpoint as a stand-in for "a direct measure of how a patient feels, functions, or survives" (FDA, 2018). Some markers, like blood pressure, have been shown to predict real outcomes. Many peptide markers have not.

  • Hormone levels. A study in healthy men showed ipamorelin triggered growth hormone release (Gobburu et al., 1999). A hormone rise is not the same as gaining muscle or strength.
  • Cell markers. The Epithalon cell study measured telomerase in a dish, yet its authors wrote of prolonging the life span of "the whole organism." Our page on reading the Epithalon literature covers that gap.
  • Direct outcomes. SELECT counted cardiovascular deaths, nonfatal heart attacks and nonfatal strokes. A primary event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group.

Is it peer-reviewed, and who paid for it?

A preprint is a paper posted before peer review. The medRxiv server says preprints "should not be relied on to guide clinical practice or health-related behavior" (medRxiv). Peer review is a check, not a guarantee, so the other questions still apply.

Funding can shape results. A 2025 meta-analysis of collagen supplements found skin benefits only in trials funded by pharmaceutical companies (Myung and Park, 2025). Our collagen peptides page covers those trials. Drug-company funding is normal for drug trials: Eli Lilly funded the retatrutide Phase 2 trial and Novo Nordisk funded SELECT. That is why registration, blinding and independent review matter.

How can you check a peptide study claim you saw online?

  1. Find the paper. Search the title or first author on PubMed, the National Library of Medicine's database of more than 40 million citations.
  2. Read the methods line. Cells, animals or people? How many people? Was there a control group?
  3. Check registration. Look for an NCT number and compare it with the ClinicalTrials.gov record.
  4. Check funding and conflicts. PubMed records often show a conflict of interest statement.
  5. Look for repeats. Do other labs, or a systematic review, find the same thing?
  6. Check the source site. MedlinePlus advises readers to "beware of dramatic writing, promises of cures, and claims that sound too good to be true" (MedlinePlus, 2024).

If a product claim cites studies, our guide to peptide pills, supplements and nasal sprays covers what FDA says about those products.

What should you do with what you find?

Bring the study to a licensed clinician or pharmacist, especially before changing any treatment. Approved peptide medicines have FDA labels and a prescriber who can weigh the evidence for you. If you want access to an investigational drug, a registered clinical trial on ClinicalTrials.gov is the legitimate route. If you have a side effect from any medical product, report it to FDA through MedWatch, or call 1-888-INFO-FDA (1-888-463-6332) and press 2.

Frequently asked questions about evaluating peptide research

Are peptides worth it?

That depends on the specific compound and its evidence, and for most research peptides the human evidence is thin or missing. Approved peptide medicines have passed FDA review for specific uses, and a prescriber decides whether one fits you.

Do any peptides have proven muscle-growth effects in people?

Not for the research peptides we checked. PubMed lists no randomized controlled trial of BPC-157. The two ipamorelin records tagged as randomized trials measured hormone release and bowel recovery, not muscle.

What are the best peptides for muscle growth?

We do not rank peptides for personal use. For BPC-157 and ipamorelin, two peptides often marketed for muscle, PubMed lists no randomized trial that measured muscle growth. A licensed clinician can discuss evidence-based options for your goals.

What should I check in a peptide study claim I saw online?

Find the original paper on PubMed. Check whether it studied cells, animals or people, how many people, and whether there was a control group. Then look for a trial registration number, the funding source, and whether other labs found the same result.

Is an animal study enough to show a peptide works in people?

No. FDA says preclinical research is not a substitute for studies in people. Many drugs that look promising early go on to fail in human trials.

What is a preprint?

A preprint is a paper shared before peer review. Preprint servers such as medRxiv state that preprints should not be relied on to guide clinical practice or health-related behavior.

What to know now

  • Who was studied: cells and animals come first; people are what count.
  • Design: randomized, blinded and placebo-controlled beats a case series.
  • Registration: look for an NCT number and check the record.
  • Replication: most BPC-157 papers come from one group, with no randomized trials in PubMed.
  • Endpoints: a hormone or cell marker is not the outcome you want.
  • Research grade: laboratory reagents for laboratory research use only, not for human or veterinary use.

What we're watching

Independent, registered human trials of popular research peptides. We also track published Phase 3 results for investigational peptides such as retatrutide.

Also in the library

Sources: U.S. Food and Drug Administration 2018, Step 2: Preclinical research; U.S. Food and Drug Administration 2018, Step 3: Clinical research; National Center for Complementary and Integrative Health. Know the Science: How to make sense of a scientific journal article (types of research, Know the Science: How to make sense of a scientific journal article; Khavinson 2003, Bulletin of Experimental Biology and Medicine; Lee 2015, Cell Metabolism; Vasireddi 2025, HSS Journal; McGuire 2025, Current Reviews in Musculoskeletal Medicine; Jastreboff 2023, New England Journal of Medicine; Lincoff 2023, New England Journal of Medicine; Beck 2014, International Journal of Colorectal Disease; Gobburu 1999, Pharmaceutical Research; International Committee of Medical Journal Editors. Clinical trial registration . https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html, Clinical trial registration; National Library of Medicine. PubMed (BPC-157 and ipamorelin searches run November 17, PubMed; U.S. Food and Drug Administration 2018, Surrogate endpoint resources for drug and biologic development; medRxiv. About medRxiv . https://www.medrxiv.org/content/about-medrxiv, About medRxiv; Myung 2025, American Journal of Medicine; MedlinePlus 2024, Evaluating health information; U.S. Food and Drug Administration 2025, Reporting serious problems to FDA (MedWatch). All 18 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (2018). Step 2: Preclinical research (content current as of January 4, 2018). https://www.fda.gov/patients/drug-development-process/step-2-preclinical-research
  2. U.S. Food and Drug Administration. (2018). Step 3: Clinical research (content current as of January 4, 2018). https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
  3. National Center for Complementary and Integrative Health. Know the Science: How to make sense of a scientific journal article (types of research, size of the study, design of the study). https://www.nccih.nih.gov/health/know-science/how-to-make-sense-of-a-scientific-journal-article/overview
  4. Khavinson, V. K., Bondarev, I. E., and Butyugov, A. A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590-592. https://pubmed.ncbi.nlm.nih.gov/12937682/
  5. Lee, C., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443-454. https://pubmed.ncbi.nlm.nih.gov/25738459/
  6. Vasireddi, N., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal, 21(4), 485-495. https://pubmed.ncbi.nlm.nih.gov/40756949/
  7. McGuire, F. P., et al. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611-619. https://pubmed.ncbi.nlm.nih.gov/40789979/
  8. Jastreboff, A. M., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. New England Journal of Medicine, 389(6), 514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
  9. Lincoff, A. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
  10. Beck, D. E., Sweeney, W. B., and McCarter, M. D. (2014). Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527-1534. https://pubmed.ncbi.nlm.nih.gov/25331030/
  11. Gobburu, J. V., et al. (1999). Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412-1416. https://pubmed.ncbi.nlm.nih.gov/10496658/
  12. International Committee of Medical Journal Editors. Clinical trial registration. https://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html
  13. National Library of Medicine. PubMed (BPC-157 and ipamorelin searches run November 17, 2026). https://pubmed.ncbi.nlm.nih.gov/about/
  14. U.S. Food and Drug Administration. (2018). Surrogate endpoint resources for drug and biologic development. https://www.fda.gov/drugs/development-resources/surrogate-endpoint-resources-drug-and-biologic-development
  15. medRxiv. About medRxiv. https://www.medrxiv.org/content/about-medrxiv
  16. Myung, S. K., and Park, Y. (2025). Effects of collagen supplements on skin aging: A systematic review and meta-analysis of randomized controlled trials. American Journal of Medicine, 138(9), 1264-1277. https://pubmed.ncbi.nlm.nih.gov/40324552/
  17. MedlinePlus. (2024). Evaluating health information. https://medlineplus.gov/evaluatinghealthinformation.html
  18. U.S. Food and Drug Administration. (2025). Reporting serious problems to FDA (MedWatch). https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda